keyword
MENU ▼
Read by QxMD icon Read
search

fluticasone

keyword
https://www.readbyqxmd.com/read/27920517/superiority-of-tiotropium-plus-olodaterol-in-comparison-with-salmeterol-plus-fluticasone
#1
COMMENT
Tomohiro Tamura, Hiroaki Satoh
No abstract text is available yet for this article.
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27919315/implication-of-alternative-minimal-clinically-important-difference-threshold-estimation-methods-on-technology-assessment
#2
Diana Brixner, Eli O Meltzer, Kellie Morland, Cathryn A Carroll, Ullrich Munzel, Brian J Lipworth
OBJECTIVES: Various minimal clinically important difference (MCID) threshold estimation techniques have been applied to seasonal allergic rhinitis (SAR). The objectives of this study are to (i) assess the difference in magnitude of alternative SAR MCID threshold estimates and (ii) evaluate the impact of alternative MCID estimates on health technology assessment (HTA). METHODS: Data describing change from baseline of the reflective Total Nasal Symptom Score (rTNSS) for four intranasal SAR treatments were obtained from United States Food and Drug Administration-approved prescribing information...
December 6, 2016: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/27913032/intervention-studies-of-inhaled-corticosteroids-combined-with-long-acting-theophylline-or-long-acting-%C3%AE-2-agonists-in-patients-with-moderate-to-severe-asthma-a-randomized-controlled-study
#3
Yan Wang, Ping Chen, Anna Dai, Shengyun Shang, Lingfei Kong
PURPOSE: To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol. METHODS: After a screening period, patients meeting the inclusion criteria were randomly assigned to the experiment group (fluticasone aerosol combined with theophylline tablets) or the control group (salmeterol/fluticasone aerosol combined with placebo tablets) for 12 weeks of treatment...
November 29, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27883019/17-oxo-dha-displays-additive-anti-inflammatory-effects-with-fluticasone-propionate-and-inhibits-the-nlrp3-inflammasome
#4
Chiara Cipollina, Serena Di Vincenzo, Liboria Siena, Caterina Di Sano, Mark Gjomarkaj, Elisabetta Pace
Chronic obstructive pulmonary disease (COPD) is characterized by reduced lung function associated with increased local and systemic inflammatory markers, such as TNFα and IL-1β. Glucocorticoids are used to treat this chronic disease, however their efficacy is low and new drugs are very much required. 17-oxo-DHA is a cyclooxygenase-2-dependent, electrophilic, α,β-unsaturated keto-derivative of docosahexaenoic acid with anti-inflammatory properties. We evaluated the action of 17-oxo-DHA alone or in combination with the steroid fluticasone propionate (FP) in peripheral blood mononuclear cells (PBMCs) from COPD patients and healthy individuals exposed to lipopolysaccharide...
November 24, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27882840/a-comparison-of-health-care-resource-utilization-and-costs-for-patients-with-allergic-rhinitis-on-single-product-or-free-combination-therapy-of-intranasal-steroids-and-intranasal-antihistamines
#5
Brooke Harrow, Ahmad R Sedaghat, Amanda Caldwell-Tarr, Robert Dufour
BACKGROUND: Allergic rhinitis (AR) is a common condition that can be treated with a number of different therapies. Treatments such as intranasal antihistamines (INAs) and intranasal steroids (INSs) are widely used by AR patients. For some allergy sufferers, a combination of therapies, specifically an INA and an INS, is required to address their symptoms. A new treatment, the formulation of azelastine hydrochloride and fluticasone pro-pionate used as a single spray (MP-AzeFlu), has become available for AR patients who need both types of treatment...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27881132/integrated-safety-and-efficacy-analysis-of-once-daily-fluticasone-furoate-for-the-treatment-of-asthma
#6
Paul M O'Byrne, Loretta Jacques, Caroline Goldfrad, Namhee Kwon, Michael Perrio, Louisa J Yates, William W Busse
BACKGROUND: Fluticasone furoate is a once-daily inhaled corticosteroid. This report provides an overview of safety and efficacy data that support the use of once-daily fluticasone furoate 100 μg or 200 μg in adult and adolescent asthma patients. METHODS: Fourteen clinical studies (six Phase II and eight Phase III) were conducted as part of the fluticasone furoate global clinical development programme in asthma. Safety data from 10 parallel-group, randomised, double-blind Phase II and III studies (including 3345 patients who received at least one dose of fluticasone furoate) were integrated to provide information on adverse events, withdrawals, laboratory assessments, vital signs and hypothalamic-pituitary-adrenal axis function...
November 24, 2016: Respiratory Research
https://www.readbyqxmd.com/read/27879191/replacement-of-sfc-dpi-with-sfc-mdi-exhaled-through-the-nose-improved-eosinophilic-chronic-rhinosinusitis-with-bronchial-asthma%C3%A2
#7
Yoshiki Kobayashi, Mikiya Asako, Takahisa Yamamoto, Hirotaka Yasuba, Koichi Tomoda, Akira Kanda
OBJECTIVE: Eosinophilic chronic rhinosinusitis (ECRS), a subgroup of chronic rhinosinusitis with nasal polyps, is a refractory disease closely associated with bronchial asthma. We recently reported on the efficacy of ultra-fine particle inhaled corticosteroids (ICS) (hydrofluoroalkane-134a-beclomethasone dipropionate: HFA-BDP) exhalation through the nose (ETN) treatment for mild-to-moderate asthmatics with ECRS. However, the effect of HFA-BDP ETN was found to be transient in some cases with severe ECRS and asthma, requiring treatment with higher-dose ICS and long-acting β2-agonists (LABA)...
November 23, 2016: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27877031/the-association-between-inhaled-corticosteroid-and-pneumonia-in-copd-patients-the-improvement-of-patients-life-quality-with-copd-in-taiwan-impact-study
#8
Cheng-Yi Wang, Chih-Cheng Lai, Wei-Chih Yang, Chia-Chieh Lin, Likwang Chen, Hao-Chien Wang, Chong-Jen Yu
To investigate the association between inhaled corticosteroid (ICS) exposure patterns and the risk of pneumonia in chronic obstructive pulmonary disease (COPD) patients, we performed a nested case-control study. Between 1998 and 2010, 51,739 patients, including 19,838 cases of pneumonia, were matched to 74,849 control subjects selected from a cohort of COPD patients using ICSs via risk-set sampling of the database constructed by the National Health Research Institutes of Taiwan. After adjusting for covariates, the current use of ICSs was associated with a 25% increase in the risk of pneumonia (odds ratio [OR] =1...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27864038/a-systematic-review-with-meta-analysis-of-fluticasone-furoate-vilanterol-combination-for-the-treatment-of-stable-copd
#9
Gustavo J Rodrigo, Hugo Neffen
BACKGROUND: Current guidelines recommend the use of inhaled corticosteroids/long-acting beta2-agonists as first-line therapy for COPD patients at risk for acute exacerbations and/or severe airflow limitation. This systematic review assesses available evidence on the efficacy and safety of fluticasone furoate/vilanterol (FF/VI) combination versus each alone, for the treatment of patients with severe to very severe stable COPD. METHODS: Randomized, placebo-controlled trials of >8 weeks of duration were included...
November 15, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27859412/oesophageal-lichen-planus-the-efficacy-of-topical-steroid-based-therapies
#10
A Podboy, D Sunjaya, T C Smyrk, J A Murray, M Binder, D A Katzka, J A Alexander, M Halland
BACKGROUND: Oesophageal lichen planus is an idiopathic inflammatory disorder characterized by significant oesophageal stricturing. Oesophageal lichen planus is a rare, difficult to diagnose, and likely an under recognized disease. As a result, there is no standardized approach to therapy and treatment strategies vary. AIM: To examine the utility of topical steroid therapy (fluticasone or budesonide) in the management of oesophageal lichen planus. METHODS: A retrospective chart review was conducted of patients diagnosed with oesophageal lichen planus who underwent baseline and follow up endoscopy pre and post topical steroid therapy between 1995 and 2016 at Mayo Clinic, Rochester MN...
November 17, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27853362/comparative-analysis-of-budesonide-formoterol-and-fluticasone-salmeterol-combinations-in-copd-patients-findings-from-a-real-world-analysis-in-an-italian-setting
#11
Valentina Perrone, Diego Sangiorgi, Stefano Buda, Luca Degli Esposti
AIM: The objective of this study was to evaluate the different outcomes associated with the use of budesonide/formoterol compared to fluticasone/salmeterol in fixed combinations in patients with COPD in a "real-world" setting. The outcomes included exacerbation rates and health care costs. PATIENTS AND METHODS: An observational retrospective cohort analysis, based on administrative databases of three local health units, was conducted. Patients with at least one prescription of fixed-dose combination of inhaled corticosteroids and long-acting β2-agonists (budesonide/formoterol or fluticasone/salmeterol), at dosages and formulations approved for COPD in Italy, between January 1, 2009 and December 31, 2011 (inclusion period), were included...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27849125/clinical-bioequivalence-of-ot329-solis%C3%A2-and-advair-diskus%C3%A2-in-adults-with-asthma
#12
Malinda V Longphre, Elise Burmeister Getz, Rick Fuller
RATIONALE: OT329 SOLIS™ is a generic candidate for the branded asthma treatment ADVAIR DISKUS® (fluticasone propionate/salmeterol xinafoate) and as such is required to provide evidence of clinical bioequivalence as a condition for regulatory approval. OBJECTIVES: The objective of the current study was to determine if SOLIS™ and DISKUS® provided "bioequivalent" improvements in lung function at two time points: Day 1 and Week 4. METHODS: This study was a randomized, multiple-dose, placebo-controlled, parallel-group design conducted in the U...
November 16, 2016: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/27825644/-variability-and-suitability-of-anti-asmathic-treatment-in-pediatric-primary-health-care
#13
Cristina Suárez-Castañón, Gracia Modroño-Riaño, Gonzalo Solís-Sánchez
OBJECTIVE: To analyse the use patterns and the characteristics of anti-asmathic prescriptions in pediatric primary health care. DESIGN: Observational and retrospective study. LOCATION: Pediatric primary health care, Asturias, Spain. PARTICIPANTS: Drug prescriptions in respiratory diseases in children (<14years old) during 2011. PRINCIPAL MEASUREMENTS: Data obtained from the billing database of the Regional Health Service of Asturias and analysed by sanitary district and primary health centres, calculating the number of DDD/1...
November 5, 2016: Atencion Primaria
https://www.readbyqxmd.com/read/27825347/non-neuronal-cholinergic-system-contributes-to-corticosteroid-resistance-in-chronic-obstructive-pulmonary-disease-patients
#14
Javier Milara, Angela Cervera, Alfredo de Diego, Celia Sanz, Gustavo Juan, Amadeu Gavaldà, Montserrat Miralpeix, Esteban Morcillo, Julio Cortijo
BACKGROUND: Inhaled corticosteroid (ICS) with long-acting beta-2 agonists is a well-documented combination therapy for chronic obstructive pulmonary disease (COPD) based on its additive anti-inflammatory properties. By contrast, the recommendation of ICS in combination with long-acting muscarinic antagonist (LAMA) is not evidence-based. In this study, neutrophils obtained from COPD patients were used to compare the anti-inflammatory effects of aclidinium bromide (a long-acting muscarinic antagonist) with corticosteroids and their potential additive effect...
November 8, 2016: Respiratory Research
https://www.readbyqxmd.com/read/27817819/efficacy-and-safety-comparison-fluticasone-furoate-and-fluticasone-propionate-after-step-down-from-fluticasone-furoate-vilanterol-in-japanese-patients-with-well-controlled-asthma-a-randomized-trial
#15
Mitsuru Adachi, Caroline Goldfrad, Loretta Jacques, Yoshie Nishimura
BACKGROUND: For patients with well-controlled asthma, 'step down' of therapy is recommended. We evaluated Japanese patients switching from inhaled corticosteroid (ICS)/long-acting beta2-agonists (LABA; equivalent to fluticasone propionate [FP]/salmeterol [SAL] 250/50 μg twice daily [BD]) to fluticasone furoate (FF)/vilanterol (VI) 100/25 μg, then stepping down to ICS alone. METHODS: This phase III trial had two treatment periods (P): P1, patients with well-controlled asthma on FP/SAL 250/50 μg BD equivalent stepped across to once daily (OD) FF/VI 100/25 μg (open-label, eight weeks); P2, patients remaining 'well controlled' after P1 stepped down to FF 100 μg OD/FP 100 μg BD/FP 250 μg BD (randomized 1:1:1, double-blind, 12 weeks)...
November 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/27817816/incidence-of-oral-thrush-in-patients-with-copd-prescribed-inhaled-corticosteroids-effect-of-drug-dose-and-device
#16
P N Richard Dekhuijzen, Maria Batsiou, Leif Bjermer, Sinthia Bosnic-Anticevich, Henry Chrystyn, Alberto Papi, Roberto Rodríguez-Roisin, Monica Fletcher, Lucy Wood, Alessandra Cifra, Joan B Soriano, David B Price
BACKGROUND AND AIMS: Little information is available on real-life occurrence of oral thrush in COPD patients treated with ICS. We investigated oral thrush incidence in COPD patients prescribed FDC ICS/LABA therapies and assessed whether it is modulated by the ICS type, dose, and delivery device. METHODS: We conducted a historical, observational, matched cohort study (one baseline year before and one outcome year after initiation of therapy) using data from the UK Optimum Patient Care Research Database...
November 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/27814453/fluctuation-analysis-of-peak-expiratory-flow-and-its-association-with-treatment-failure-in-asthma
#17
David A Kaminsky, Lucy L Wang, Jason H T Bates, Cindy Thamrin, David M Shade, Anne E Dixon, Robert A Wise, Stephen Peters, Charles G Irvin
RATIONALE: Temporal fluctuations have been demonstrated in lung function and asthma control, but the effects of controller therapy on these fluctuations is unknown. OBJECTIVE: We hypothesized that fluctuations in peak expiratory flow (PEF) are predictive of subsequent treatment failure and may be modified by controller therapy. METHODS: We applied detrended fluctuation analysis to once-daily PEF data from 493 participants in the Leukotriene Modifier Corticosteroid or Corticosteroid-Salmeterol (LOCCS) trial of the American Lung Association Airways Clinical Research Centers...
November 4, 2016: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27767328/effect-of-fluticasone-furoate-and-vilanterol-on-exacerbations-of-copd-in-patients-with-moderate-airflow-obstruction
#18
Fernando J Martinez, Jørgen Vestbo, Julie A Anderson, Robert D Brook, Bartolome R Celli, Nicholas J Cowans, Courtney Crim, Mark Dransfield, Sally Kilbride, Julie Yates, David E Newby, Dennis Niewoehner, Peter Ma Calverley
BACKGROUND: Inhaled corticosteroids have been shown to decrease exacerbations in COPD patients with moderate to severe COPD. Their effect in patients with milder airflow obstruction remains unclear. OBJECTIVE: This was an analysis of exacerbations in the Study to Understand Mortality and MorbidITy (SUMMIT) study. DESIGN: In a double-blind randomized controlled trial, once daily inhaled placebo, fluticasone furoate (FF, 100 μg), vilanterol (VI, 25 μg) or the combination (FF/VI) was administered...
October 21, 2016: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27766109/adrenal-suppression-in-children-treated-with-swallowed-fluticasone-and-oral-viscous-budesonide-for-eosinophilic-esophagitis
#19
Alexandra Ahmet, Eric I Benchimol, Ellen B Goldbloom, Janice L Barkey
BACKGROUND: Adrenal suppression (AS), a glucocorticoid (GC) side effect associated with significant morbidity, is well described related to inhaled corticosteroid therapy for asthma. Swallowed topical glucocorticoid therapy is the main pharmacotherapy treatment for eosinophilic esophagitis (EoE) and therefore children with EoE are potentially at increased risk of AS. METHODS: In this prospective cohort study, we included children and youth <18 years diagnosed with EoE and treated with swallowed fluticasone or oral viscous budesonide for more than 1 month...
2016: Allergy, Asthma, and Clinical Immunology
https://www.readbyqxmd.com/read/27764539/different-anti-remodeling-effect-of-nilotinib-and-fluticasone-in-a-chronic-asthma-model
#20
Hye Seon Kang, Chin Kook Rhee, Hea Yon Lee, Hyoung Kyu Yoon, Soon Seok Kwon, Sook Young Lee
Background/Aims: Inhaled corticosteroids are the most effective treatment currently available for asthma, but their beneficial effect against airway remodeling is limited. The tyrosine kinase inhibitor nilotinib has inhibitory activity against c-kit and the platelet-derived growth factor receptor. We compared the effects of fluticasone and nilotinib on airway remodeling in a chronic asthma model. We also examined whether co-treatment with nilotinib and fluticasone had any synergistic effect in preventing airway remodeling...
October 20, 2016: Korean Journal of Internal Medicine
keyword
keyword
30179
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"